Trelegy™ Ellipta™ which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/04/2018|
|Rapid review completed||18/06/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy™ Ellipta™ be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement; August 2018